Mixed-model imputation of cost data for early discontinuers from a randomized clinical trial

Drug Information Journal

Volumn 33, Issue 1, 1999, Pages 191-209

  Obenchain, Robert L ^a   Johnstone, Bryan M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

'Time is money' Survival curves; Bootstrap inference in cost effectiveness; Mixed linear models; Single and multiple imputation; Variance component heterogeneity

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG RESEARCH; HUMAN; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STATISTICAL MODEL;

EID: 0032966610     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300123     Document Type: Article

References (33)

1. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
2. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73:13-22.
3. Diggle P, Kenward MG. Informative dropout in longitudinal data analysis (with discussion). App Stat. 1994;43:49-93.
4. Diggle PJ, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. Oxford Statistical Science Series, vol. 13. Oxford: Oxford University Press; 1994.
5. Little RJA. Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc. 1995; 90:1112-1121.
6. Hogan JW, Laird NM. Intention-to-treat analyses for incomplete repeated measures data. Biometrics. 1996;52:252-267.
7. Little R, Yau L. Intention-to-treat analyses for longitudinal studies with drop-outs. Biometrics. 1996;52: 1324-1333.
8. Smith F. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (cognex®) in alzheimer's patients. J Biopharm Stat. 1996; 6:59-67.
9. Wolfinger RD. Heterogeneous variance-covariance structures for repeated measures. J Agricul Biolog Environ Stat. 1996;1:205-230.
10. Rosenheck R, Cramer J, Weichuh X et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Eng J Med. 1997;337:809-815.
11. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York, NY: John Wiley and Sons; 1987.
12. Efron B. Missing data, imputation, and the bootstrap. J Am Stat Assoc. 1994;89:463-479.
13. Lavori PW, Dawson R, Shera D. A multiple imputation strategy for clinical trials with truncation of patient data. Stat Med. 1995;14:1913-1925.
14. Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc. 1996;91:473-489.
15. Jennrich RI, Schluchter MD. Incomplete repeated-measures model with structured covariance matrices. Biometrics. 1986;42:805-820. [Concepts first implemented in BMDP 5V software.]
16. Littell RC, Freund RJ, Spector PC. SAS System for Linear Models. Third edition. Cary, NC: SAS Institute; 1991.
17. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute; 1997.
18. Vonesh EF, Chinchilli VM. Linear and Nonlinear Models for the Analysis of Repeated Measurements. New York, NY: Marcel Dekker; 1997.
19. Wolfinger RD. An example of using mixed models and proc MIXED for longitudinal data. J Biopharm Stat. 1997;7:481-500.
20. Rutten-Van Molken MPMH, Van Doorslaer EKA, Van Vliet RCJA. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ. 1994;3:333-345.
21. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme M. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
22. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems; 1986.
23. Duan N. Smearing estimate: A nonparametric retransformation method. J Am Stat Assoc. 1983;78: 605-610.
24. Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials. 1986;7:267-275.
25. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53: 457-481.
26. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6:461-464.
27. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53:419-434.
28. Etzioni RD, Feuer EJ, Sullivan SD, Lin D, Hu C, Ramsey S. On the Use of Survival Analysis Techniques to Estimate Medical Care Costs. Seattle, WA: Fred Hutchinson Cancer Research Center; 1997.
29. Heyse J, Carides G, Cook J. Statistical analysis of treatment cost data subject to censoring. 20th Mid-western Biopharmaceutical Statistics Workshop. Muncie, IN: Ball State University; 1997.
30. Williams RL. Product-limit survival functions with correlated survival times. Lifetime Data Anal. 1995; 1:171-186.
31. Obenchain RL, Melfi CA, Croghan TW, Buesching DP. Bootstrap analyses of cost-effectiveness in antidepressant pharmacotherapy. PharmacoEcon. 1997; 11:464-472.
32. Obenchain RL. Issues and algorithms in cost-effectiveness inference. Biopharma Report. 1997;5:1-7.
33. Obenchain RL. CEplane: Microsoft Windows Software for Cost-Effectiveness Confidence Intervals. Copyright © Pharmaceutical Research and Manufacturers of America; URL www.math.iupui.edu/ ∼indyasa/download.htm; 1998.